Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Anticoagulation Therapy on Clinical Outcomes in Moderate to Severe Coronavirus Disease 2019 (COVID-19)

Next Previous
Search
Trial Profile

Effect of Anticoagulation Therapy on Clinical Outcomes in Moderate to Severe Coronavirus Disease 2019 (COVID-19)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary) ; Heparin; Low molecular weight heparins
  • Indications COVID 2019 infections; Deep vein thrombosis; Myocardial infarction; Pulmonary embolism; Stroke; Thromboembolism; Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms COVID-PREVENT

    • Most Recent Events

    • 01 Nov 2023 Primary endpoint (Seven-category ordinal scale recommended by the WHO) has not been met according to Results published in the Clinical Research in Cardiology.
    • 01 Nov 2023 Primary endpoint (D-dimer level) has not been met according to results published in the Clinical Research in Cardiology.
    • 01 Nov 2023 Results of the COVID-PREVENT randomized controlled trial published in the Clinical Research in Cardiology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top